Evaluating treatment effectiveness of peripartum cardiomyopathy by 99mTc-MIBI SPE MPI
Author:
Affiliation:
Fund Project:
摘要
|
图/表
|
访问统计
|
参考文献
|
相似文献
|
引证文献
|
资源附件
|
文章评论
摘要:
目的:利用核素心肌灌注显像观察围产期心肌病(perfusion of peripartum cardiomyopathy,PPCM)治疗前与治疗后左室形态大小及左室各壁心肌血流灌注的变化。方法:27例 PPCM患者,女性,年龄19~38岁。对其行控制心力衰竭及防止心室重构治疗,分别于治疗前、治疗后1月[(29.41±2.95) d]行静息心肌灌注显像;其中11例患者进行了6月[(6.31±0.84)月]随访复查。将左室分为17节段进行评分,采用半定量分析方法评价治疗前、后左室大小,放射性分布稀疏缺损范围及左室各节段评分的变化。结果:治疗后早期与治疗前心肌灌注显像相比,23例患者(85%)左心室缩小,放射性分布稀疏缺损范围缩小(P=0.001),心肌各节段(除前间壁基底段及后间壁基底段外)评分增加(Pmax=0.024);治疗后半年与治疗后早期比较,其中7例患者(64%)左心室大小恢复正常,放射性分布稀疏缺损范围进一步缩小(P=0.009),放射性分布稀疏缺损节段评分进一步增加(Pmax=0.048)。结论:99mTc-MIBI SPE MPI心肌灌注显像可用于评价PPCM的治疗效果。
Abstract:
Objective:To observe the morphology of left ventricle and changes in myocardial perfusion of peripartum cardiomyopathy (PPCM) before and after treatment by 99mTc-MIBI SPE MPI. Methods:Twenty-seven female patients with PPCM averaged 19-38 year-old were enrolled. Treatment preventing cardiac failure and ventricular remodeling were performed on them. 99mTc-MIBI SPE MPI was applied at one month((29.41±2.95) d) after the treatment. Eleven patients were followed-up for six months((6.31±0.84)months). Left ventricle was divided into 17 segments and semi quantitative assessment was performed to evaluate the morphology of left ventri-cle,perfusion defect range and changes in left ventricular segmental score before and after the treatment. Results:Left ventricular size was decreased in 23 patients(85%),perfusion defect range was decreased(P=0.001) and myocardial perfusion was increased in all left ventricular segments except basal segment of anterior wall and basal segment of posterior wall(Pmax=0.024) at early stage of treat-ment compared with those before treatment. Left ventricular size was normal in 7 patients(64%),perfusion defect range was further decreased in 11 patients(P=0.009) and myocardial perfusion was further increased(Pmax=0.048) after 6 months’ treatment compared with those before treatment. Conclusion:99mTc-MIBI SPE MPI can be used to assess treatment in patients with peripartum cardiomy-opathy.